Table 3.
AEs attributable to treatment
| AEs | Primary PD-(L)1 Resistance (N=30) | Acquired PD-(L)1 Resistance (N=28) | ||||
| Grade | Grade | |||||
| 3 | 4 | 5 | 3 | 4 | 5 | |
| Atrial fibrillation | 1 (3) | |||||
| Atrial flutter | 1 (3) | |||||
| Chills | 1 (3) | |||||
| Confusion | 1 (4) | |||||
| Creatinine increased | 1 (4) | |||||
| Death NOS | 1 (4) | |||||
| Dehydration | 1 (3) | 2 (7) | ||||
| Diarrhea | 1 (3) | 3 (11) | ||||
| Dyspnea | 4 (13) | 1 (4) | ||||
| Encephalopathy | 1 (4) | |||||
| Fatigue | 1 (3) | |||||
| Febrile neutropenia | 1 (4) | |||||
| Generalized muscle weakness | 1 (4) | |||||
| Hyperglycemia | 1 (4) | |||||
| Hypoxia | 1 (3) | 1 (4) | ||||
| Lung infection | 1 (3) | 1 (4) | ||||
| Lymphocyte count decreased | 1 (3) | 1 (4) | 1 (4) | |||
| Nausea | 1 (4) | |||||
| Neutrophil count decreased | 1 (4) | |||||
| Platelet count decreased | 1 (3) | 1 (3) | 1 (4) | |||
| Pneumonitis | 1 (3) | 1 (4) | ||||
| Rash maculopapular | 1 (4) | |||||
| Vomiting | 1 (4) | |||||
| White blood cell decreased | 1 (4) | |||||
| Maximum grade any AE | 9 (30) | 1 (3) | 6 (21) | 2 (7) | 2 (7) | |
Values are n (%).
AE, adverse event; NOS, not otherwise specified; PD-L1, programmed death ligand 1.